Division of Allergy Pulmonary and Critical Care Medicine Archive — Page 8 of 12
-
July 23, 2020
Rice named to new leadership role for VICTR operations
Todd Rice, MD, MSc, has been appointed vice president for Clinical Trial Innovation and Operations in the Vanderbilt Institute for Clinical and Translational Research (VICTR). -
July 8, 2020
New clues to lung-scarring disease may aid treatment
Scientists at Vanderbilt University Medical Center and the Translational Genomics Research Institute (TGen) in Phoenix, Arizona, have discovered previously unreported genetic and cellular changes that occur in the lungs of people with pulmonary fibrosis (PF). -
June 4, 2020
Remdesivir helps reduce COVID-19 recovery time: study
The investigational antiviral drug remdesivir can shorten the time to recovery in adults hospitalized with COVID-19, according to preliminary results of a clinical trial published last month in The New England Journal of Medicine. -
May 27, 2020
Study to test cognitive rehab therapy for ICU survivors
Vanderbilt University Medical Center will study adult survivors of medical and surgical intensive care at high risk for long-term cognitive impairment to see if computerized cognitive rehabilitation (CCR) is effective in improving cognition in ICU survivors who often have trouble doing complex tasks, maintaining their finances and staying employed. -
May 27, 2020
Research probes why COVID-19 seems to spare young children
Lung disease experts at Vanderbilt University Medical Center (VUMC) and their colleagues have determined a key factor as to why COVID-19 appears to infect and sicken adults and older people preferentially while seeming to spare younger children. -
May 12, 2020
Study to determine rate of novel coronavirus infection in U.S. children
Researchers at Vanderbilt University Medical Center (VUMC) are leading a nationwide study to determine the rate of novel coronavirus infection in U.S. children and their families. -
April 2, 2020
Progression of inflammatory lung disease analyzed
A Vanderbilt University Medical Center interim analysis shows that there appears to be a considerable length of time before a subset of people develop inflammatory, scarring lung diseases where there is radiologically detectable evidence they will develop lung disease.